Zinc Bioglasses Regulate Mineralisation in Human Dental Pulp Stem Cells

Mei Huang \(^1, 2, *\), Robert G. Hill\(^2\), Simon C.F. Rawlinson\(^1\)

1. Institute of Dentistry, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, UK

2. Institute of Dentistry, Dental Physical Sciences Unit, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, UK

*Correspondence to: Mei Huang, Institute of Dentistry, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, UK.

Email: mei.huang@qmul.ac.uk
Abstract

**Objective:** A promising strategy in regenerative endodontics is the combination of human dental pulp stem cells (hDPSCs) with an appropriate biomaterial substrate. The effects of zinc and zinc containing bioactive glasses (ZnBGs) on hDPSCs have been characterised in this study.

**Methods:** ZnBGs were designed and produced. Then the odontogenic differentiation and mineralisation potential of hDPSCs upon ZnBGs treatment were investigated.

**Results:** Free Zn ions (0-5 ppm) enhanced proliferation and alkaline phosphatase (ALP) activity of hDPSCs. Further, ZnBGs conditioned medium (ZnBG-CM) increased the production and secretion of odontogenic markers: dentine sialophosphoprotein (DSPP), dentine matrix protein 1 (DMP-1). In addition, we identified that mRNA expression of the osteogenic markers RUNX2, OCN, BSP, BMP-2, MEPE and ON was increased following treatment with ZnBG-CM. Long term treatment with ZnBG-CM increases the formation rate of mineralised nodules (similar to hydroxyapatite, Ca:P=1.6), as confirmed by scanning electron microscopy combined with energy dispersive X-ray spectroscopy (SEM-EDX). Lastly, the administration of ZnBG-CM induces VEGF expression.

**Significant:** These findings implicate that ZnBG would be beneficial in regenerative endodontics and could influence the way present Zn containing clinical products are used.
Zinc Bioglasses Regulate Mineralisation in Human Dental Pulp Stem Cells

1. Introduction

The high incidence of tooth decay and tooth loss combined with the limited regeneration capacities of dental tissues necessitates the development of novel strategies for dental practices [1]. Human dental pulp stem cells (hDPSCs) are a mesenchymal stem cell (MSC) population [2, 3]. Analogous to MSCs derived from bone marrow (BMSCs), hDPSCs can form alizarin red-positive mineralised deposits, physiologically similar to hydroxyapatite (HA) [2, 4]. Thus, experiments have been conducted to evaluate the value of hDPSCs in the repair of bone defects [5-7]. However, numerous studies have demonstrated that hDPSCs have a greater ability to differentiate into odontoblasts compared to BMSCs [2, 8]. Co-transplanting cultured hDSPCs with HA/TCP particles, into immunocompromised mice, led to the vascularisation of a fibrous pulp tissue surrounded by a layer of odontoblast-like cells, cells had extended tubular structures that resembling a dentine-like structure [2, 8]. In contrast, a lamellar bone structure with associated adipose tissue was formed by human BMSCs under the same experimental condition [2]. These findings clearly demonstrate distinct tissue regeneration capacities of hDPSCs and BMSCs, which appear to have maintained a level of epigenetic memory of their tissue origin [2]. Somewhat unsurprisingly then, hDPSCs is the preferred derivation of cells for dental tissue engineering.

The fundamental concept in hard tissue engineering lies in combining a scaffold with living cells to repair damaged tissue [9]. Scaffolds provide a suitable environment for cell attachment, proliferation, differentiation and to promote bio-mineralisation [10]. A significant challenge regarding scaffold usage is the choice of a suitable material. A broad range of materials, natural or synthetic polymers and inorganics, have been designed as scaffolds for dentin-pulp regeneration [11]. Bioactive glasses (BGs) are a promising choice for repair and
reconstruction of hard tissues, such as bone and dentine [12, 13]. BGs can form hydroxyapatite (HA) quickly, is biocompatible and can deliver ‘therapeutic ions’ [12, 14].

In dental practice, the use of zinc (Zn) is mostly favoured owing to its bacteriostatic and cariostatic properties [15]. For example, Zn oxide eugenol (ZOE), Zn oxyphosphate (ZOP), and Zn polycarboxylate (ZPC) are widely used. However, despite the clinical advantages, the dentinogenic benefits of Zn have yet to be determined. Accordingly, we have focused on Zn and Zn containing BGs (ZnBGs) to characterise their effects on hDPSCs.

2. Materials and methods

2.1. Bioactive glass synthesis and characterisation

ZnBGs (compositions are shown in Fig.2A) were synthesised by the melt-quench route [16]. Glass frits were grounded and sieved to powders ≤ 38µm. The particle size and amorphous nature was confirmed by master particle size analyser and X-ray diffraction (XRD). ZnBGs powders were characterised as described previously [17]. Briefly, 75mg of BGs powder (≤ 38 µm) was added to 50 ml Tris buffer and incubated on an orbital shaker (60 rpm at 37 °C). Post shaking, the pH values were recorded. The solution was filtered, diluted by a factor of ten in distilled H₂O and acidified with 69% nitric acid (final concentration 2%) prior to determining the elemental concentrations of calcium (Ca), phosphorus (P), silica (Si), and zinc (Zn) using an inductively coupled plasma-optical emission spectrometer (ICP-OES). The residual powders were dried overnight and analysed to evaluate the extent of apatite formation using XRD, and Fourier transform infrared spectroscopy (FTIR).

2.2. Cell culture

Human dental pulp stem cells (hDPSCs, Lonza) were cultured in Dulbecco's Modified Eagle Medium (DMEM, Lonza) supplemented with 10% fetal calf
serum (FCS) and antibiotics (10U/L penicillin and 100mg/L streptomycin) in a humidified atmosphere with 10% CO\textsubscript{2} at 37 °C.

Free ionic Zn (0.5, 1, 5, 10 and 20 ppm) was added as ZnCl\textsubscript{2}. ZnBG conditioned medium (ZnBG-CM) was prepared by immersing 75mg of glass powders in 50ml DMEM for set periods of time. Before being added to the cells, ZnBG-CM was filter-sterilized, serum and antibiotics were added and equilibrated to 37°C, 10% CO\textsubscript{2} in an incubator.

Cells between passages 3-5 were used in all experiments. For cell proliferation, MTT and ALP activity assays, 1000 cells/well were seeded in 96-well plates and cultured for 1, 4, 7 and 10 days. 1×10\textsuperscript{5} cells/dish and 2×10\textsuperscript{4} cells/well were placed in 10cm dishes and 6-well plate for Western blot and qPCR studies, respectively. 5×10\textsuperscript{3} cells were seeded onto sterilised coverslips and placed in 12-well plates for immunocytochemistry. 24-wells plate with 5×10\textsuperscript{3} cells/well was used for the mineralisation study.

2.3. MTT activity assay

The MTT activity assay reflects mitochondrial activity-an indication of viable cells. After rinsing twice with PBS, 50μl of MTT solution (5mg/ml MTT in PBS) was added to cell culture and incubated for 4 hrs at 37°C. After this, medium was removed and the formazan was solubilised in 100μl dimethyl sulfoxide (DMSO). The absorbance of the solubilised formazan supernatant was measured at 560nm.

2.4. Quantitative assay of ALP activity

Alkaline phosphatase (ALP) activity was measured by adding 100μl of ALP reaction solution (20mg 4-Nitropheyl-phosphate disodium salt hexahydrate tablet dissolved in 8ml Tris buffer solution (pH=9.5) containing 15μl of 2M MgCl\textsubscript{2}) to cell lysate, incubated in the dark at 37°C for 1 hr. Afterwards, the reaction was stopped by adding 50 μl of 1M NaOH. The absorbance of the supernatant was measured at 405nm and ALP activity was calculated according to a standard curve (Fig.S1).
2.5. Crystal violet staining

Cells were fixed with 10% neutral buffered formalin for 15 min, rinsed twice with PBS and stained in 0.5% (w/v) crystal violet for 15 min at room temperature. Before visualising, the unbound stains were removed by extensive washing in PBS.

2.6. Western Blot analysis

Cell pellets were re-suspended in RIPA buffer (containing 1% Triton X-100 and 1% cocktail proteinase inhibitors) and the protein content measured using DC™ Protein Assay. Intracellular expression of dentin sialophosphoprotein (DSPP), dentin matrix acidic phosphoprotein 1 (DMP-1) and vascular endothelial growth factor (VEGF) was evaluated by Western blotting using indicated antibodies (Table.A.1) on a PVDF membrane. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the loading control. Cell culture supernatant was also collected and analysed for DSPP and DMP-1 secretion, Coomassie blue was used to visualise sample separation. The band densities were quantified by ImageJ software.

2.7. Immunocytochemistry

4% paraformaldehyde in PBS was used to fix the cells. Subsequently, cells were permeabilised with 0.1% Triton X-100 for 10 min, and incubated with 10% goat serum for 30 min to block nonspecific binding. Following 1 hr incubation in primary antibody (Table.S1) at room temperature, cells were washed and incubated with secondary antibody for 1 hr and counter stained with DAPI. Finally, the cells were mounted on slides and viewed under confocal microscopy (LSM710, Zeiss). The images were then analysed with ImageJ software.

2.8. Quantitative real-time polymerase chain reaction-qPCR

Message RNA (mRNA) was isolated from cells with Dynabeads® (Thermo Fisher Scientific) and reverse-transcribed into cDNA using Transcriptor cDNA Synthesis Kit (Roche). The forward and reverse primers used for PCR were
designed by Roche universal probe library according to the complementary DNA sequences available in GenBank (Table.S2). qPCR amplifications were performed on LightCycler 480 qPCR system (Roche) using LightCycler® 480 SYBR Green I Master. For each PCR reaction, 2μl of 10 fold-diluted cDNA was used for amplification of the target genes. The thermal cycling conditions were as follows: 95°C for 5 min and 55 cycles of 95°C for 10s, 60°C for 6s, 72°C for 6s, 76°C for 1s. Relative expression levels of runt-related transcription factor 2 (RUNX2), osteonectin (ON), osteocalcin (OCN), bone sialoprotein (BSP), matrix extracellular phosphoglycoprotein (MEPE), and bone morphogenetic protein 2 (BMP-2) were determined with reference to GAPDH.

2.9. Alizarin Red S staining

After 3, 4 and 5 weeks culture, cells were fixed in 4% glutaraldehyde for 30min and stained with 2% Alizarin Red S (Sigma-Aldrich) for 1 hr at room temperature. After three washes in dH₂O to remove unbound stain, samples were air-dried and photographed. For quantification, the bound stain was extracted with 10% cetylpyridinium chloride, and the absorbance of solution was measured at 560 nm.

2.10. Scanning electron microscope (SEM)

Cells were fixed in 2.5% glutaraldehyde for 1 hr and dehydrated in graded ethanol (50%, 70%, 80%, 90%, 95%, and 100%), followed by critical-point drying with hexamethyldisilazane. The samples were coated with carbonate and viewed using SEM with an energy-dispersive X-ray (EDX) detector operated from 10-20 kV to scan and analyse mineralised nodule formation and composition.

2.11. Statistical analysis

Statistical analysis was performed using GraphPad Prism 5. All data were collected from three independent experiments and presented as mean ± standard deviation (SD). Differences were considered significant at p<0.05,
determined using one-way ANOVA with Bonferroni’s post hoc multiple comparison test.

3. Results

3.1. Low dose Zn increases hDSPCs proliferation and ALP activity

Cells were treated with Zn (0.5 to 20 ppm) for 1, 4, 7 and 10 days. Zn at low concentrations (0.5 and 1 ppm) showed no significant effect on cell proliferation (Fig.1A) as determined by MTT activity assays. Zn at 5 ppm significantly increased (*p<0.05) cell proliferation. However, Zn at high doses (10 and 20 ppm) significantly reduced (*p<0.05) both cell proliferation. A significant increase (*p<0.05) in ALP activity is observed at low concentrations of Zn (0.5 and 1 ppm) treatment for 7-10 days (Fig.1B). At 20 ppm, Zn reduced ALP activity (Fig.1B) due to increased cytotoxicity as visualised by crystal violet staining (Fig.1C).

3.2. Characterisation of ZnBGs

The amorphous nature of the ZnBGs was indicated by broad peaks in the XRD patterns (Fig.2B). Similar particle size distribution was confirmed by particle size analysis (Fig.S2A).

To evaluate bioactivity of the ZnBGs, immersion in Tris buffer was performed. An increase in pH was measured after immersion (Fig.S2B). The XRD and FTIR studies confirmed that Zn incorporation retards apatite formation in a dose-dependent manner (Fig.2C-F). Consistent with XRD findings, the FTIR data also suggested that Zn delays apatite formation (Fig.S3). ICP-OES analysis revealed rapid release of P and Ca ions from the glass within the first 6 hrs of immersion, these were then incorporated into apatite, hence the reduction of measurable levels. The concentration of Si increased continuously due to the continuous glass dissolution. Interestingly, no particular release pattern was observed for Zn (Fig. 2G-J), but the Zn concentration in all samples was less than 1ppm.
3.3. ZnBG-CM regulates hDPSC behaviour and processing of DSPP and DMP-1

hDPSCs were treated with ZnBG-CM. MTT assay demonstrated that ZnBG-CM has no significant effect on cell proliferation after 1 and 4 days of treatment. Cell proliferation was increased in Zn1, Zn2 and Zn3 BG-CM treatment groups by day 7 and 10. Enhanced ALP activity was detected in hDPSCs following treatment with Zn3 BG-CM by day 1. However, by day 7 and 10, a significant increase (*p<0.05) in ALP activity was detected in all ZnBG-CM treatments when compared with the control group (Fig. 3B).

To further investigate the influence of ZnBGs on the odontogenic differentiation of hDPSCs, the regulation of two odontogenic markers - DSPP and DMP-1 was determined by Western blot and immunocytochemistry. As shown in Fig.3C, multiple bands were detected in DSPP and DMP-1 immunoblotting, that are indicative of protein processing as reported previously [18]. Densitometry analysis revealed that intracellular DSPP levels were significantly increased (*p<0.05) upon all ZnBG-CM treatment and intracellular DMP-1 levels were only enhanced in Zn2 and Zn3 BG-CM treatment for 7 days in culture. However, prolonged treatments that extend for 14 days suggested a reduction in intracellular DSPP and DMP-1 levels (Fig.3D). Immunoblotting of cell culture supernatant reflected the secretion of these two proteins (Fig.3E), where only DMP-1, but not DSPP, secretion is significantly increased (*p<0.05) following ZnBG-CM treatment (Fig.3F).

Immunocytochemistry and confocal microscopy analysis demonstrated that DSPP is localised to nucleus and perinuclear region (confirmed by co-staining with the Golgi marker GM130, Fig.4A and C). Further, DSPP localisation to Golgi was induced following ZnBG-CM treatment (Fig.4B and C). DMP-1 is shown to be localised in both cytosol and nucleus (Fig.4A) and no change in its localisation pattern is induced by ZnBG-CM treatment (Fig.S4).

3.4. ZnBG induces mineralisation of hDPSCs
The mineralisation potential of hDPSCs following ZnBG-CM treatment was assessed by Alizarin Red S that stains Ca\(^{2+}\) deposits red (Fig.5A). Quantification of the staining demonstrated significant increases (*p<0.05) in the staining induced by treatment with Zn1, Zn2 and Zn3 BG-CM by week 3, 4 and 5 in comparison to the glass free control group. SEM scans revealed that the mineralised nodules generated by hDPSCs were between 50 and 100µm in diameter and were raised from the culture surface (Fig.5C). EDX spectra for calcium and phosphate content in the mineralised nodules indicated a ratio of Ca:P similar to that of hydroxyapatite (~1.6, Fig.5C).

3.5. ZnBG modulates mineralisation-associated gene expression

Further regulation of mineralisation-related differentiation markers of hDPSCs was investigated by qPCR. This analysis revealed up-regulation of *BSP* and *MEPE* by day 7 and 14 following all conditions of ZnBG-CM treatment (Fig. 5G and H). High expression levels of *RUNX2* and *BMP-2* were detected for Zn1, Zn2 and Zn3 groups but not Zn0 group. Differential expression was observed for *ON*, when compared to other groups, and *OCN* is increased only by groups Zn0 and Zn3 at day 7. However, by day 14, the mRNA level of all the genes was up-regulated following ZnBG-CM treatment irrespective of the Zn content (Fig.5D-I).

3.6. ZnBG modulation of VEGF levels

Following ZnBG-CM treatment immune blotting and densitometry analysis revealed that Zn1 and Zn3 groups clearly enhanced intracellular VEGF levels in hDPSCs after 7 days. Furthermore, by day 14 the expression of VEGF was significantly increased (*p<0.05) in all ZnBG-CM treatments (Fig 5J-K).

4. Discussion

The use of 45S5® BG in regenerative endodontics for pulp capping demonstrated the formation of a reparative dentine bridge [19, 20]. The amorphous BG is generally more soluble and reactive than crystalline materials,
such as calcium phosphate, thereby enhancing the bioactivity of the material. In addition, BGs can be manufactured to release ‘therapeutic’ ions, which may induce accelerated formation of mineralised tissues. As Zn is already widely used in dentistry, we have investigated the effect of ZnBGs on differentiation and mineralisation of hDPSCs.

Initially, the safe range of free Zn ion was accessed in cultures of hDPSCs. Cell proliferation and ALP activity assays suggested that low dose Zn, from 0 to 5 ppm, is not cytotoxic and induces the proliferation and differentiation of hDPSCs. High concentrations (10 and 20ppm) are toxic (Fig. 1). These findings suggested that ZnBG might also be able to positively modulate hDPSCs odontogenic behaviour.

The influence of Zn on the bioactivity process and its role in BG structure has been extensively debated in literature [21]. ZnO can either act as a modifier leading to a decrease in surface area and pore size of the BG [22]. ZnO can also act as an intermediate oxide forming covalent links between adjacent SiO$_4$ tetrahedra [23] to create a more stable glass structure. In this study, Zn was added to the BGs assuming that it behaves entirely as an intermediate oxide. The ZnBGs were successfully synthesised as amorphous structures. The bioactivity of these ZnBGs was quantified (assessed by apatite formation) when immersed in a relevant physiological fluid. [24]. XRD and FTIR findings both confirmed that Zn addition to BG delays the apatite formation in a dose-dependent manner (Fig. 2). This agrees with previous findings, where delayed apatite formation was due to an increase in the network polymerisation with the incorporation of Zn [25].

To determine any biological effect, ZnBG-CMs were used in cell culture. At early time points (1 and 4 days), ZnBG-CMs showed no effect on cell proliferation, thereafter increased cell proliferation was observed by day 7 and 10 (Fig. 3). These findings indicate that these novel ZnBGs have no significant cytotoxic effects on hDPSCs, confirming the possible utilisation of these materials in tissue repair. The observed increase in ALP activity with ZnBG
treatment over time indicates the differentiation potential of hDPSCs and confirmed by the subsequent increase in mineralisation (Fig. 3).

Protein levels of the odontogenic markers DSPP and DMP-1 were quantified to determine odontogenic differentiation of hDPSCs following ZnBG-CM treatment (Fig. 3). DSPP and DMP-1 are both involved in the nucleation and formation of HA during dentine formation [26]. Multiple bands were observed in DSPP and DMP-1 blotting, that reflect small functional cleavage products: dentine sialoprotein (DSP) and dentine phosphoprotein (DPP) [26]. Densitometry analysis revealed DSPP levels were increased by day 7 and reduced by day 14. Meanwhile, immunocytochemistry and confocal microscopy analysis revealed DSPP localisation to Golgi was induced upon ZnBG-CM treatment (Fig. 4). This implies that ZnBG increases intracellular DSPP protein levels, and subsequently processed in Golgi as reported previously [18]. Increases in DMP-1 levels and secretion are detected as two fragments: N-terminal (37kDa) and C-terminal fragments (57kDa) [26], was also observed following ZnBG-CM treatment (Fig.4E). However, no changes in DMP-1 cellular localisation were observed in response to ZnBG-CM treatment. These findings lend support to the idea that ZnBGs in part induce odontogenic differentiation of hPDSCs. PCR analysis also revealed increase in both DSPP and DMP-1 mRNA expression along with osteogenic markers (RUNX2, BMP1, BSP, ON, OCN, and MEPE), which are crucial genes associated with critical roles in mineralisation [27-29]. These results are consistent with previous investigation showing that Zn added BG granules stimulate growth and osteogenic differentiation of MSCs via regulation of ALP activity and BSP expression [30]. Together, these findings suggest that ZnBGs can enhance differentiation of hDPSCs in a fashion similar to osteoblast differentiation. This in turn impacts on the mineralisation potential of hDPSCs, as observed in our studies by Alizarin Red S staining and SEM-EDX (Fig. 5). Moreover, western blot analysis reveals that the expression of VEGF is increased following ZnBG-CM treatment. This is in agreement with a previous report that VEGF plays an essential role in the regulation of mineralisation by stimulating differentiation of MSCs [31]. VEGF has also been confirmed to promote odontogenic differentiation of hDPSCs in vitro [32, 33].
In a similar study, the stimulation of odontogenic differentiation of dental pulp cells following ZnBG incorporated cement treatment was reported. In addition, this ZnBG incorporated cement up-regulated the expression of VEGF and the increased the tubular structure in endothelial cells [34]. The findings in present study, in consistent with the previous investigation [34], clearly indicate that ZnBGs can promote the generation of mineralised nodules via up-regulation of VEGF in both osteogenic and odontogenic differentiation pathways in hDPSCs. It also raises the question, what effect are clinical treatments that contain Zn having on the local cells, and especially odontoblasts?

5. Conclusion

Stem cell-based regenerative endodontics is a new and exciting field that has the potential to transform the dental practice. In this study, novel zinc containing bioactive glasses were successfully designed and synthesised. Biological studies demonstrated activity of the odonto/osteogenic and VEGF pathways that might be the mechanism by which Zn induces the differentiation of hDPSCs. This study raises the intriguing possibility of using ZnBGs as therapeutic scaffolds in regenerative endodontics.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgements

The authors would like to thank China Scholarship Council (CSC) for the joint PhD studentship program with Queen Mary University of London. The authors would like to thank BALM imaging facilities at Blizard Institute Queen Mary University of London. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.

Reference:

Figure Legends:

Figure 1. Effects of free Zn ion on hDPSCs. (A): MTT activity of hDPSCs treated with Zn (0-20ppm). Data is presented as fold change upon comparison with Zn 0ppm group at day 1. (B): ALP activity of hDPSCs following Zn (0-20ppm) treatment. The ALP activity was measured in each group and normalised to cell number. (C): Crystal violet staining of hDPSCs after 10 days exposure to Zn (0-20ppm). Scale bar = 100 μm. All the data are expressed as mean±SD from
three independent experiments. * indicates significance value of p<0.05 when compared to Zn 0ppm group.

**Figure 2. Characterisation of ZnBGs.** (A): ZnBG compositions, the network connectivity for all the ZnBGs are fixed at 2.1. (B): XRD patterns of all unreacted BGs confirm amorphous nature. (C) - (F): XRD pattern of ZnBGs after Tris buffer dissolution from 0 to 168 hrs, two peaks at 2θ 26 and 32 2θ indicate apatite formation. (G) - (J): ICP-OES analysis of ZnBGs after immersion in Tris buffer for 168 hrs. All ionic (P, Ca, Si, and Zn) data in ppm was plotted as a function of time.

**Figure 3. Effects of ZnBG on odontogenic differentiation.** (A): Cell proliferation of hDPSCs treated with ZnBG-CMs was assessed by MTT activity assay. Data is presented as a fold change compared to negative control group at day 1 (B): ALP activity of hDPSCs following ZnBG-CMs treatment. The ALP activity was measured in each group and normalised to cell number. (C): Western blot analysis of intracellular DSPP and DMP-1 expression, GAPDH expression was used to determine the loading control. Lane 1-5: Negative control (NC), Zn0, Zn1, Zn2 and Zn3 BG-CM, respectively. (D): Relative intensities of intracellular DSPP and DMP-1 to GAPDH were obtained, and then compared to NC group to determine the fold change. (E): Western blot analysis for secreted DSPP and DMP-1. Coomassie blue staining was used as loading control. The lanes setup is same as in (C). (F): Relative intensities of secreted extra cellular DSPP and DMP-1 were obtained by Coomassie blue staining, and then compared to NC group to determine fold changes. All data were expressed as mean±SD from three independent experiments, * indicates significance of p<0.05.

**Figure 4. ZnBGs regulate DSPP and DMP-1 localisation in hDPSCs.** (A): Representative images show staining of DSPP and DMP-1 in red for hDPSCs. Scale bar = 8µm. (B): Representative images of DSPP and GM130 (Golgi marker) staining in hDPSCs following ZnBG-CM treatment. Images show DSPP (green) and Golgi (red) and cell nuclei (blue). Scale bar = 30µm. (C): The colocalisation of DSPP (green) and GM130 (red) in hDPSCs was quantified and represented in bar chart after treated with ZnBG-CMs Scale bar = 8µm. Data was expressed as mean±SD from three independent experiments, and * denotes p<0.05 significance where indicated.

**Figure 5. ZnBG-CM regulates mineralisation and osteogenic differentiation of hDPSCs.** (A): Representative images show Alizarin Red S staining indicating mineralisation (in red colour) of hDPSCs. (B): Quantification of Alizarin Red S staining in hDPSCs was presented as a fold change compared to negative control (NC) group. (C): SEM-EDX analysis of mineralised nodules generated in hDPSCs. (D)-(I): qPCR analysis of RUNX2, ON, OCN, BSP, MEPE and BMP-2 expression in DPSCs following ZnBG-CM treatment for 7 and 14 days. The expression level of each gene was normalized to GAPDH (reference gene). Fold change was determined by comparing to NC group at day 7. (J): Western blot analysis of intracellular VEGF expression, and GAPDH levels were determined for loading control. Lane1-5: NC, Zn0, Zn1, Zn2 and Zn3-BGCM. (D): Relative intensities of VEGF in reference to GAPDH were determined and expressed as fold change in comparison to, NC. All the data were expressed as mean±SD from three independent experiments, and the significance is denoted as *p<0.05, **p<0.01 where indicated.
ZnBG compositions in mol% with a fixed network connectivity of 2.1.

---

### Table 1: ZnBG Compositions

<table>
<thead>
<tr>
<th>Glass</th>
<th>SiO₂</th>
<th>Na₂O</th>
<th>CaO</th>
<th>P₂O₅</th>
<th>ZnO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zn0</td>
<td>38.5</td>
<td>26.2</td>
<td>29</td>
<td>6.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Zn1</td>
<td>37.0</td>
<td>26.5</td>
<td>29.2</td>
<td>6.3</td>
<td>1.0</td>
</tr>
<tr>
<td>Zn2</td>
<td>35.7</td>
<td>26.7</td>
<td>29.4</td>
<td>6.2</td>
<td>2.0</td>
</tr>
<tr>
<td>Zn3</td>
<td>34.3</td>
<td>27.0</td>
<td>29.6</td>
<td>6.1</td>
<td>3.0</td>
</tr>
</tbody>
</table>

---

### Figures

- **Figure A**: Table showing ZnBG compositions.
- **Figure B**: Graph showing intensity vs. 2θ for different ZnBG compositions.
- **Figure C**: Graph showing intensity vs. 2θ for Zn0 with different reaction times.
- **Figure D**: Graph showing intensity vs. 2θ for Zn1 with different reaction times.
- **Figure E**: Graph showing intensity vs. 2θ for Zn2 with different reaction times.
- **Figure F**: Graph showing intensity vs. 2θ for Zn3 with different reaction times.
- **Figure G**: Graph showing P ppm vs. Time (hrs) for different ZnBG compositions.
- **Figure H**: Graph showing Ca ppm vs. Time (hrs) for different ZnBG compositions.
- **Figure I**: Graph showing Si ppm vs. Time (hrs) for different ZnBG compositions.
- **Figure J**: Graph showing Zn ppm vs. Time (hrs) for different ZnBG compositions.